复宏汉霖：HLX22乳腺癌治疗II期临床试验完成首例患者给药

Core Insights - The company Fuhong Hanlin has announced the completion of the first patient dosing in the Phase II clinical trial of its innovative anti-HER2 monoclonal antibody HLX22, in combination with Trastuzumab, for the treatment of HER2 low-expressing HR-positive locally advanced or metastatic breast cancer [1] Group 1 - The Phase II clinical study (HLX22-BC201) has been completed for the first patient in China [1] - The treatment area for HLX22 has expanded to include breast cancer, following its application in HER2-positive gastric cancer [1]